Propanc Biopharma (PPCB) AI Stock Analysis

• Market Cap: $2.16M
• Dividend Yield: N/A
• Average Volume (3M): 400.33K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.58
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 1
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 15,859,280
• 10 Day Avg. Volume: 553,394
• 30 Day Avg. Volume: 400,327
• PEG Ratio: <0.01
• Price to Book (P/B): 1.18
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -40.64
• Enterprise Value/Market Cap: 1.52
• Enterprise Value/Revenue: 109.63
• Enterprise Value/Gross Profit: 24.84K
• Enterprise Value/Ebitda: -0.05
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $0.12 ▼(-47.27% Downside)
• Action: Upgraded Date: 03/13/26
• Date: Action: Upgraded 03/13/26

The score is primarily weighed down by very weak financial performance (minimal revenue, large losses, and ongoing cash burn) and strong technical deterioration (price far below key moving averages with bearish momentum). Corporate events add meaningful risk due to Nasdaq bid-price noncompliance, while valuation metrics provide limited support given negative earnings and no dividend data.

Positive Factors

Low financial leverage

Very low reported debt (debt-to-equity ~0.01) gives Propanc structural financial flexibility and reduces near-term insolvency risk. For a pre-commercial biotech, low leverage lowers fixed obligations, preserving optionality to time financing and partnerships to advance R&D over the next several quarters.

Experienced scientific leadership

Adding Dr. Ralf Brant, a veteran with decades in drug discovery and >50 compounds advanced to clinic, strengthens scientific governance and translational expertise. This improves long-term R&D decisionmaking, trial design and partner credibility—key for advancing preclinical assets into clinical stages.

Promising lead preclinical data (PRP)

PRP's reported preclinical effects—high tumor growth inhibition, reduced fibrosis, and activity versus cancer stem cells—suggest differentiated mechanism and combination potential with chemo. Structurally, robust preclinical efficacy increases probability of partnerships, licensing interest and clinical development pathways.

Negative Factors

Minimal revenue / pre-commercial

With essentially no commercial revenue (~$0.03M TTM) and prior years showing no sales, the company remains pre-commercial. Over the medium term this means operations must be funded externally, and long-term viability depends on successful clinical progression rather than current operating performance.

Sustained negative cash flow

Consistent negative operating and free cash flow (~-$3.1M TTM) indicates ongoing cash burn and inability to self-fund development. Structurally, this forces recurring equity or partnership financings, increasing dilution risk and potentially slowing R&D timelines if capital markets tighten.

Nasdaq listing noncompliance risk

Nasdaq minimum bid-price noncompliance creates delisting risk and could materially hinder liquidity and access to public capital. Over months, this structural issue can raise financing costs, reduce attractiveness to partners, and impair ability to offer equity incentives essential for small biotech execution.

Propanc Biopharma Business Overview & Revenue Model

Company Description

Propanc Biopharma, Inc., a biopharmaceutical company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. The company has a research collaboration with University of Jaén to commence the POP1 joint drug discovery program. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.

How the Company Makes Money

null

Propanc Biopharma Financial Statement Overview

Summary

Very weak operating profile: TTM revenue is minimal (~$0.03M) with deeply negative profitability and large net losses. Cash flow remains consistently negative (TTM operating and free cash flow about -$3.1M), indicating ongoing cash burn and reliance on external funding. A key offset is low reported leverage (debt-to-equity ~0.01) and a recent swing to positive equity, but fundamentals are still dominated by pre-commercial execution and financing risk.

Income Statement

TTM (Trailing-Twelve-Months) shows only ~$0.03M of revenue with a modest gross margin (~21%), but profitability is extremely weak with very large operating and net losses (net margin deeply negative). Annual results historically show no revenue for multiple years, suggesting the business remains pre-commercial and dependent on funding rather than operating scale. Strength: some gross profit in TTM; Weakness: losses are overwhelmingly disproportionate to revenue and have recently expanded materially.

Balance Sheet

Leverage appears low in TTM with minimal debt relative to equity (debt-to-equity ~0.01), which is a positive for financial flexibility. However, returns remain very negative (TTM return on equity around -6), indicating ongoing value erosion. The balance sheet also shows prior periods with negative equity (2021–2024), followed by a sharp swing to positive equity in 2025 annual data—an improvement, but also a sign the capital structure may have changed materially and could be less stable/recurring than operating performance.

Cash Flow

Cash generation is weak: TTM operating cash flow and free cash flow are both negative (~-$3.1M), reflecting continued cash burn. While free cash flow growth is shown as improving, the company still does not fund operations internally, and cash outflows are large relative to the current revenue base. Strength: cash burn appears to have improved versus some prior periods; Weakness: still consistently negative cash flow with no clear self-sustaining operating cash profile.

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	29.90K	0.00	0.00	0.00	0.00	0.00
Gross Profit	132.00	0.00	-21.66K	-17.76K	-5.67K	0.00
EBITDA	-62.93M	-58.34M	-1.26M	-2.23M	-2.14M	-1.69M
Net Income	-66.07M	-58.92M	-1.82M	-2.66M	-2.66M	-2.03M
Balance Sheet
Total Assets	15.11M	19.63M	72.36K	60.33K	81.65K	13.10K
Cash, Cash Equivalents and Short-Term Investments	561.24K	12.09K	21.09K	10.05K	4.07K	2.25K
Total Debt	1.68M	1.73M	948.27K	545.92K	1.04M	680.08K
Total Liabilities	4.66M	5.73M	3.85M	3.18M	3.11M	3.08M
Stockholders Equity	10.45M	13.91M	-3.78M	-3.12M	-3.02M	-3.07M
Cash Flow
Free Cash Flow	-3.10M	-405.17K	-935.12K	-1.11M	-1.44M	-1.15M
Operating Cash Flow	-3.10M	-405.17K	-935.12K	-1.11M	-1.44M	-1.15M
Investing Cash Flow	-4.76K	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	3.69M	490.76K	941.89K	1.11M	1.49M	1.06M

Propanc Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VRCA	47 Neutral	$105.99M	―	252.30%	―	234.73%	81.16%
BRNS	46 Neutral	$27.78M	-0.43	-70.57%	―	-100.00%	-26.30%
PPCB	41 Neutral	$2.16M	-0.58	-1163.67%	―	―	―

Propanc Biopharma Corporate Events

Propanc Biopharma Announces Board Change and New Appointment

On February 20, 2026, Propanc Biopharma announced that long‑time board member Dr. Julian Kenyon retired and stepped down from its Board of Directors to concentrate on his personal and family life, though he will continue to serve as a medical advisor to the company. On the same date, the board filled the resulting vacancy by appointing pharmaceutical and oncology research executive Dr. Ralf Brant, whose more than three decades of experience in drug discovery, pre‑clinical development, and translational oncology, including advancing over 50 compounds into clinical studies, is expected to strengthen Propanc’s scientific oversight and governance.

The most recent analyst rating on (PPCB) stock is a Sell with a $0.21 price target. To see the full list of analyst forecasts on Propanc Biopharma stock, see the PPCB Stock Forecast page.

Propanc Biopharma Receives Nasdaq Minimum Bid Price Notice

On December 31, 2025, Propanc Biopharma received a notice from Nasdaq that its common stock no longer met the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market, after trading below that threshold for 35 consecutive business days. The company has until June 30, 2026, to regain compliance—either by its share price closing at or above $1.00 for at least ten consecutive business days or, if eligible, by using an additional 180-day compliance period that could include a reverse stock split—while its stock remains listed for now and business operations and SEC reporting are not immediately affected; however, potential delisting could reduce liquidity, hinder capital-raising efforts, limit access to public markets, and weaken its ability to offer equity incentives, posing significant risks to shareholders and corporate financing.